Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Institutional & Insider Ownership
25.9% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Cellectis shares are held by institutional investors. 9.9% of Zynerba Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Zynerba Pharmaceuticals and Cellectis’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zynerba Pharmaceuticals||$10,000.00||15,094.70||-$23.38 million||($2.59)||-4.30|
|Cellectis||$56.46 million||20.78||-$67.25 million||($2.81)||-11.62|
Zynerba Pharmaceuticals has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Zynerba Pharmaceuticals and Cellectis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Zynerba Pharmaceuticals and Cellectis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zynerba Pharmaceuticals currently has a consensus price target of $18.15, suggesting a potential upside of 62.93%. Cellectis has a consensus price target of $39.83, suggesting a potential upside of 22.00%. Given Zynerba Pharmaceuticals’ higher possible upside, analysts plainly believe Zynerba Pharmaceuticals is more favorable than Cellectis.
Zynerba Pharmaceuticals beats Cellectis on 9 of the 13 factors compared between the two stocks.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.